Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2) : a randomised, double-blind, placebo-controlled, phase 3 trial

Authors
Publication date
1 January 2020
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Institutional Repository Universiteit Antwerpen

    redirect
    oaic:irua:180601
    Last time updated on 30/08/2022